Regeneron
FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients
March 12, 2019Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma
Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …
Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron
February 26, 2019Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma
Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …
Sanofi will pay Regeneron $582m in deal restructuring
January 7, 2019Sales and Marketing Deals, Regeneron, Sanofi, biotech, pharma
French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal …
Allergan strengthens Finance Leadership Team with two appointments
December 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, MIT, Regeneron, appointment, pharma
The Dublin-headquartered multinational Allergan has appointed two experienced pharma investors to its Finance Leadership Team. The biopharmaceutical firm yesterday announced …
Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration
August 20, 2018Sales and Marketing Bayer, Eylea, FDA, Regeneron, US, pharma
Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the …
Regeneron Pharma and Bluebird bio announce immune cell collaboration
August 6, 2018Sales and Marketing Cancer, Regeneron, Shares, bluebird, collaboration, t cells, t-cells
Regeneron Pharmaceuticals have announced that they will collaborate with the Massachusetts-based gene therapy specialist Bluebird bio in an effort to …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Sanofi/Regeneron forced to slash price in wake of slow sales
May 1, 2018Research and Development, Sales and Marketing Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical, praluent
Sanofi and Regeneron were touted as having a sure-fire blockbuster on their hands when they first brought Praluent to market …
Regeneron-Alnylam team up to treat NASH
March 22, 2018Research and Development, Sales and Marketing Alnylam, Regeneron, biotech, drugs, nash, pharma, pharmaceutical
Coming on the back of a Regeneron research piece published in the New England Journal of Medicine, the company announced …
Regeneron’s Eylea smashes Phase 3 trial goal in diabetic retinopathy
March 20, 2018Manufacturing and Production, Research and Development Eylea, Regeneron, diabetes, pharma
Regeneron has confirmed that its vascular endothelial growth factor (VEGF) inhibitor injection Eylea (aflibercept) met its primary endpoint in a …
Sanofi and Regeneron reveal strong data and a price drop for Praluent
March 12, 2018Research and Development, Sales and Marketing Regeneron, Sanofi, pharma, praluent
Sanofi and Regeneron have revealed strong new data for its PCSK9 inhibitor Praluent showing the first-ever reduction in deaths within …
Appeal could throw spanner in the works for Regeneron’s Irish expansion
March 9, 2018Manufacturing and Production, Medical Communications Ireland, Regeneron, pharma
Regeneron is facing a single man-sized obstacle in plans to expand operations at its campus in Limerick, Ireland with a …
Top Ten most popular articles on Pharmafile.com this week
February 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Alzheimer's, AstraZeneca, Eylea, FDA, Microsoft, Regeneron, Shire, Tremfya, eurordis, multiple myeloma, rare disease
It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …
Reports increasing of worrying side-effects with Regeneron’s Eylea
February 22, 2018Medical Communications, Research and Development, Sales and Marketing Eylea, FDA, Regeneron, pharma
Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …
Regeneron forced to drop Eylea combo, advantage Novartis
November 27, 2017Manufacturing and Production, Research and Development Eylea, Novartis, Regeneron, biotech, drugs, pharma, pharmaceutical
Novartis released Phase 3 data on its leading candidate for wet age-related macular degeneration (AMD) drug and it caused a …
